Related Experiment Video
Updated: Feb 17, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway
1School of Nursing, Fujian University of Traditional Chinese Medicine, Fujian 350122, People's Republic of China.
Abstract:
Although dexamethasone (DEX) remains a first-line agent for multiple myeloma (MM) therapy, the development of DEX resistance has become an indicator of poor prognosis in MM patients. It is thus urgent to develop strategies to restore the vulnerability of MM to DEX. This study demonstrated long non-coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1) was highly expressed in DEX-resistant myeloma cell lines, and upregulation of NEAT1 was tightly linked to poor prognosis. The in-depth study revealed that during the development of DEX resistance in these cells, the miR-193a levels were decreased, which resulted in the increased expression of the target gene myeloid cell leukemia-1 (MCL1). We also found knockdown of NEAT1, the DEX-induced sensitivity was enhanced in the resistant cells. Meanwhile, overexpression of NEAT1 increased the DEX-induced resistance in the sensitive cells. In conclusion, the NEAT1/miR-193a/MCL1 pathway is closely associated with the development of DEX resistance in myeloma cells, and knockdown of NEAT1 can significantly improve DEX sensitivity in MM.
Insights
Dexamethasone resistance in multiple myeloma is a poor prognostic indicator. This study found that targeting NEAT1 can restore myeloma cell sensitivity to dexamethasone, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Dexamethasone (DEX) is a primary treatment for multiple myeloma (MM).
- DEX resistance in MM correlates with poor patient outcomes.
- Developing strategies to overcome DEX resistance is crucial for MM treatment.
Purpose of the Study:
- To investigate the role of long non-coding RNA NEAT1 in DEX resistance in MM.
- To elucidate the molecular mechanisms underlying DEX resistance involving NEAT1.
Main Methods:
- Analysis of NEAT1 expression in DEX-resistant MM cell lines.
- Investigating the relationship between NEAT1, miR-193a, and MCL1 expression.
- Assessing the impact of NEAT1 knockdown and overexpression on DEX sensitivity.
Main Results:
- NEAT1 was highly expressed in DEX-resistant MM cells and linked to poor prognosis.
- Decreased miR-193a levels and increased MCL1 expression were observed during DEX resistance development.
- NEAT1 knockdown enhanced DEX sensitivity in resistant cells, while overexpression induced resistance in sensitive cells.
Conclusions:
- The NEAT1/miR-193a/MCL1 pathway is implicated in the development of DEX resistance in MM.
- Targeting NEAT1 presents a potential strategy to improve DEX sensitivity in MM patients.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Related Concept Videos
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs
Abnormal Proliferation